<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03214003</url>
  </required_header>
  <id_info>
    <org_study_id>2017YJZ19</org_study_id>
    <nct_id>NCT03214003</nct_id>
  </id_info>
  <brief_title>Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC</brief_title>
  <acronym>TRISS</acronym>
  <official_title>Twice-daily Radiotherapy by Simultaneous Integrated Boosting Technique Versus Twice-daily Standard Radiotherapy for Patients With Limited-stage Small Cell Lung Cancer: a Multicenter, Randomized, Controlled, Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anhui Shi, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin Provincial Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Air Force General Hospital of the PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multicenter, perspective, non-blinded, randomized controlled phase 3 trial.
      In order to establish whether the SIB technique can improve the results of twice-daily
      chemo-RT for patients with LS-SCLC, the investigators will primarily compare survival of
      patients treated with standard chemotherapy (cisplatin and etoposide) and either SIB
      twice-daily RT or standard dose twice-daily RT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three hundred and twenty-six patients with a histological or cytological proven diagnosis of
      SCLC will be recruited from 35 centers in 14 areas including provinces, municipalities and
      autonomous region, from May 2017 to May 2020.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>from the starting date of treatment until the date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Progression Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>from the starting date of treatment until the date of local disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>from the staring date of treatment until the date of distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>up to 5 months</time_frame>
    <description>at baseline, the beginning of radiotherapy and treatment completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute and late toxicity</measure>
    <time_frame>up to 5 years</time_frame>
    <description>from treatment starting to treatment completion, every 1 week; from treatment completion to 2 year, every 3 months; from 2 year to 5 year, every 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">326</enrollment>
  <condition>Small Cell Lung Cancer Limited Stage</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>SIB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive concurrent twice-daily radiotherapy by SIB technique (95%PGTV 54Gy, 95%PTV 45Gy,both in 30 twice-daily fractions over 3 weeks, 5 days per week) and chemotherapy (etoposide and cisplatin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BID group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive concurrent twice-daily standard radiotherapy (95%PTV 45Gy in 30 twice-daily fractions over 3 weeks, 5 days per week, without SIB) and chemotherapy (etoposide and cisplatin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SIB</intervention_name>
    <description>patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy</description>
    <arm_group_label>SIB group</arm_group_label>
    <other_name>chemotherapy with etoposide and cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard</intervention_name>
    <description>patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy</description>
    <arm_group_label>BID group</arm_group_label>
    <other_name>chemotherapy with etoposide and cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Read the patient information and Sign the informed consent before enrollment

          -  Either sex, age ≥18 and ≤70

          -  Histologically or cytologically confirmed SLCL

          -  Limited stage disease(AJCC, 2009 version 7), stage I-III(T any, N any, M0) that can be
             safely treated with definitive radiation doses, excludes T3-4 due to multiple lung
             nodules that are too extensive or have tumor/nodal volume that is too large to be
             encompassed in a tolerable radiation plan, clinical nonmalignant diagnosis by
             investigator when the pleural is too few to obtain cytological evidence.

          -  measurable lesion according RECIST 1.1

          -  PS ECOG 0-1

          -  having zero to two cycles of systemic chemotherapy with etoposide and cisplatin
             (cisplatin 60-80 mg/m2 at day1 or divided into two to three days, etoposide 100-120
             mg/m2 at day 1 to 3, Q21d, and the treatment delay between two cycles shouldn't be
             more than 14days).

          -  patients especially female patients must satisfy the investigator that they are not
             pregnant, or are not of childbearing potential, or are using adequate contraception.
             Man must also use adequate contraception

          -  adequate haematological function: white blood cell ≥3.0×109/L , neutrophils
             ≥1.5×109/L, platelet ≥100×109/L, hemoglobin ≥90g/L.

          -  adequate liver and renal function: total bilirubin ≤1.5 ×upper limit normal , alanine
             transaminase and aspartate aminotransferase ≤1.5 ×upper limit normal, normal serum
             creatinine and/or calculated creatinine clearance ≥60ml/min.

        Exclusion Criteria:

          -  prior surgical resection of the primary tumor or prior RT for lung cancer

          -  mixed small-cell and non-small-cell histological features

          -  contemporaneous immunotherapy or target therapy

          -  pregnancy or lactation

          -  physical or mental disease that could impact treatment plan

          -  unable to understand the trial, or could not follow the process

          -  to refuse the sign the informed consent.

          -  no history of previous malignancy in the past 5 years (except non-melanomatous skin or
             in situ servix carcinoma)

          -  be allergic to any known protocol in this trail

          -  be enrolled in other clinical trial in past 30days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anhui Shi, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Anhui Shi, MD</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <keyword>small cell lung cancer limited stage</keyword>
  <keyword>twice-daily radiotherapy</keyword>
  <keyword>simultaneous integrated boosting technique</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

